Lecanemab in Early Alzheimer’s DiseaseChristopher H. van Dyck, Takeshi Iwatsubo|New England Journal of Medicine|2022Cited by 5k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseSamantha Budd Haeberlein, Alfred Sandrock, Paul Aisen et al.|The Journal of Prevention of Alzheimer s Disease|2022Cited by 1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseStephen Salloway, Michael Grundman, Reisa A. Sperling et al.|Neurology|2009Cited by 739
Trial of Solanezumab in Preclinical Alzheimer’s DiseaseReisa A. Sperling, Paul Aisen, Michael Donohue et al.|New England Journal of Medicine|2023Cited by 382
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Alison Goate et al.|Nature Medicine|2021Cited by 365